Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 228 results
Page 1 of 46   

Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

Principal Investigator: David Bender, MD

Department:Obstetrics/ Gynecology

Participants in this study have uterine cancer that has re-grown or has not responded to prior treatment. The purpose of this study is to find out if the study drug, Ixabepilone, works in treating this type of cancer and to find out what side effects are caused by treatment with this drug. In addition to the treatment part of this study, the researchers plan to test samples of the tumor (if available from a previous surgery).  The purpose of this research is to determine if this testing can be used in the future to determine ahead of time which patients may respond to treatment or have good prognosis. Approximately 10 people will take part in this study conducted by investigators at the University of Iowa. Participation in this study will last as long as there is evidence that the tumor is not growing and there are no serious side effects.

age group:18 to 99 years trial start date:May 25, 2011
Gender Preference:female Trial End Date: May 25, 2021
Contact Info:

Sharon Stockman, (319) 356-2015

Keywords: 201104768 ; Bender ; cancer ; Carcinosarcoma ; Carcinosarcoma in uterus ; Phase two

LY2875358 + Erlotinib & LY2875358 Monotherapy, MET Positive NSCLC w/ Resistance to Erlotinib

Principal Investigator:Taher Abu Hejleh, MD

Department:Hematology/Oncology

The purpose of this study is to test the effectiveness of the research study drugs LY2875358 and erlotinib in making tumors smaller in patients with metastatic non-small cell lung cancer.
This is a research study to test the effectiveness of LY2875358 and erlotinib, also known as "investigational." This means the drug has not been approved by the U.S. Food and Drug Administration (FDA) for the use described in this study. However, the FDA has allowed the use of this drug for research.

About 100 people will be enrolled in the study.

age group:18 to 99 years trial start date:April 1, 2014
Gender Preference:none Trial End Date: November 1, 2014
Contact Info:

Taher Abu Hejleh     319-353-7381     taher-hejleh@uiowa.edu

Keywords: Abu Hejleh ; Cancer ; erlotinib therapy ; Lung ; Phase 2 ; Phase ii

LEE011 + letrozole in postmenopausal women w/ hormone receptor pos, HER2-neg, advanced breast cancer

Principal Investigator: Alexandra Thomas

Department:Hematology/Oncology

Participants in this study have been diagnosed with breast cancer. Studies have shown that blocking a certain pathway has the potential to control ER+ breast cancer progression. The purpose of this study is to test the efficacy of using LEE011 in combination with letrozole to prolong progression free survival in postmenopausal women with advanced breast cancer.
About 500 participants will take part in this study at multiple sites; approximately 16 participants will take part in this study at the University of Iowa.

age group:18 to 99 years trial start date:April 21, 2014
Gender Preference:female Trial End Date: December 3, 2014
Contact Info:

Alexandra Thomas     319-356-1770

Keywords: Breast ; Cancer ; letrozole ; Phase 3 ; Phase iii ; Thomas

Phase II Study of Abraxane & Bevacizumab vs Ipilimumab for Stage IV Metastatic Malignant Melanoma

Principal Investigator:Mohammed Milhem, MD

Department:Hematology/Oncology

Participants in this research study have Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative). Participants will receive either the drugs nab-paclitaxel( Abraxane®) and bevacizumab (Avastin®) or the commonly-used drug ipilimumab. The purpose of this study is to compare whether the study drugs nab-paclitaxel and bevacizumab keep cancer from getting worse for a longer period of time.

Approximately 16 people will take part in this study conducted by investigators at the University of Iowa. Up to 176 people will take part in this study at approximately 11 sites in the Midwest Melanoma Partnership group.

age group:18 to 99 years trial start date:April 14, 2014
Gender Preference:none Trial End Date: December 1, 2015
Contact Info:

Mohammed Milhem     319-356-2324     mohammed-milhem@uiowa.edu

Keywords: Abraxane ; Bevacizumab ; Cancer ; Ipilimumab ; Melanoma ; Milhem ; Phase 2 ; Phase ii

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Principal Investigator: Joseph Cullen MD

Department:GI Surgery

Participants in this study have been diagnosed with adenocarcinoma of the pancreas, a type of pancreatic cancer. The purpose of this study is to see if using pharmacological ascorbate and gemcitabine chemoradiation is safe and effective in treating pancreatic cancer. Approximately 30 people will take part in this study at the University of Iowa.

age group:18 to 99 years trial start date:January 21, 2014
Gender Preference:none Trial End Date: October 31, 2017
Contact Info:

Joseph Cullen     319-353-8297

Keywords: Cancer ; Cullen ; Pancreatic ; phase 1 ; phase i
Page 1 of 46
« 1 2 3 4 5  ... » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x